Endomag wins CE Mark for Magseed MIS breast cancer guide, inks 5-year distro deal

UK-based surgical guidance company Endomag said this week it won CE Mark approval in the European Union for its Magseed minimally invasive breast marker and that it inked a 5-year distribution deal with Sysmex.

The company’s Magseed is designed to mark tumor sites with a ‘seed’, which it says is smaller than a grain of rice, up to 30 days prior to surgery. Endomag claims the procedure to implant the device takes only a few minutes, and that it cannot be dislodged before surgery.

During the operation, the surgeon can use the company’s Sentimag device to locate the tumor before making an incision, reducing surgery invasiveness and providing opportunities for better cosmetic outcomes.

“After the successful launch of Magseed in the US, where many of the top cancer centres are now using it routinely, we couldn’t wait to make it available across Europe. Sysmex’s experience with the Sentimag and Sienna system makes it an ideal partner for Magseed, and Sysmex has demonstrated its ability to successfully launch and grow sales of our products across the EMEA region. Together, we can now offer the first radiation-free surgical guidance platform for both lesion localisation and sentinel node biopsy using a single instrument,” CEO Eric Mayes said in a prepared statement.

Endomag said the system will be distributed through the Europe, the Middle East and Africa by Sysmex, which it’s had a partnership with since 2013.

“We’re pleased to extend our partnership with Endomag, which has proven its ability to successfully address genuine unmet needs. Our commitment to another five years demonstrates our confidence in Endomag and the Sentimag platform. We are delighted with this opportunity to introduce Magseed. We will now be able to deliver a safer, more efficient workflow for cancer centres that we believe will help them be more efficient and more effective. This is perfectly in line with our mission of shaping the advancement of healthcare for the benefit of patients and our clients alike,” Sysmex oncology senior VP Ines Groener said in a press release.

The post Endomag wins CE Mark for Magseed MIS breast cancer guide, inks 5-year distro deal appeared first on MassDevice.

from MassDevice http://ift.tt/2xFN7o4